Martek Stock Climbs 45%; Do Future Gains Lie Beyond Infant Formula?
This article was originally published in The Tan Sheet
Executive Summary
Martek Biosciences' long-awaited launch of its DHA and ARA nutritional oils in U.S. infant formula has garnered Wall Street's enthusiasm, but continued investor confidence could hinge on the fortified products' commercial success, as well as Martek's ability to expand beyond the infant formula market